Headquartered in San Rafael, CA Fiscal year ends December NASDAQ: BMRN biomarin.com
BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for people living with genetically defined conditions. Founded in 1997, the company has nine commercial therapies spanning bone growth disorders, lysosomal storage diseases, phenylketonuria (PKU), and gene therapy. Its portfolio includes VOXZOGO (for achondroplasia with a pending hypochondroplasia indication), VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA, ALDURAZYME, KUVAN, ROCTAVIAN (being discontinued), and the newly acquired GALAFOLD and POMBILITI + OPFOLDA (from the April 2026 acquisition of Amicus Therapeutics). BioMarin's pipeline includes BMN 333 (long-acting CNP for achondroplasia), BMN 351 (for Duchenne muscular dystrophy), BMN 820 (oral CCR2 inhibitor for FSGS), and a collaboration with the n-Lorem Foundation for ReNU syndrome. The company trades on NASDAQ under the ticker BMRN. Updated
Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that…
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except…
Pre-Market Stock Futures: Futures are trading lower as we get set to start the new trading week, as reports indicate that President Trump declined Iran’s counteroffer for peace. This comes after a…
Pre-Market Stock Futures: The futures are trading lower as we get set to start a new trading week, and after last week’s string of record highs, it may be tough to duplicate…
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
BioMarin Pharmaceutical (Nasdaq: BMRN | BMRN Price Prediction) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading. Let’s dig into what happened in…
Eric Bleeker Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Coherent, Coinbase Global, Conagra Brands, Coty, Hertz Global, Netflix, Plug Power, Rivian Automotive, Transocean, United States Steel and Vici Properties.
Wednesday's top analyst upgrades and downgrades included Amazon.com, BioMarin Pharmaceutical, Constellation Brands, Dominion Energy, Lucid, Nike, Southern Company, Tesla, Valero Energy, Walgreens Boots Alliance and Wells Fargo.
Wednesday's top analyst upgrades and downgrades included Alphabet, Danaher, Emerson Electric, Foot Locker, GoDaddy, Harley-Davidson, Meta Platforms, New York Community Bancorp, Nvidia, Prologis, Rio Tinto, Simon Property and Vornado Realty Trust.
Friday's top analyst upgrades and downgrades included Adobe, Citigroup, FedEx, Foot Locker, Hewlett Packard Enterprise, Intel, Medical Properties Trust, Nike, Qualcomm, Skyworks Solutions, Takeda Pharmaceutical and Under Armour.
Wednesday's top analyst upgrades and downgrades included BioMarin Pharmaceutical, BlackRock, CF Industries, Constellation Energy, DocuSign, DraftKings, Mosaic, Norfolk Southern, Nvidia, RingCentral, Riot Platforms and SentinelOne.
These five top Goldman Sachs Conviction List stock picks have the largest upside to the firm's target prices. Growth investors concerned about market and economic uncertainty may want to have them in…
Wednesday's top analyst upgrades and downgrades included APA, Delta Air Lines, Generac, Lululemon Athletica, Microchip Technology, Paccar, Philip Morris International, Pinduoduo, Shopify, Taboola.com and Welltower.
Wednesday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Eli Lilly, Home Depot, Medtronic, Palantir Technologies, Snowflake, Take-Two Interactive Software, Viatris and Walgreens Boots Alliance.
BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for people living with genetically defined conditions.
24/7 Wall St.'s 12-month price target for BMRN is $60.78, rated Buy. The Wall Street consensus target is $91.62. BMRN price prediction →
